Burden of bleeding related episodes in patients with immune thrombocytopenic purpura despite treatment with Eltrombopag or Romiplostim which aims to prevent these episodes: a real world, retrospective study

Trial Profile

Burden of bleeding related episodes in patients with immune thrombocytopenic purpura despite treatment with Eltrombopag or Romiplostim which aims to prevent these episodes: a real world, retrospective study

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Eltrombopag (Primary) ; Romiplostim (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Oct 2017 New trial record
    • 12 Oct 2017 Results presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top